Paris, January 4th, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism, announces today the closing of an equity financing led by Primer Capital. The financing round includes investments in equity from Primer Capital and historical shareholders Anaxago, CapDecisif Management and private investors for €1,7 million and grants from Concours Mondial de l’Innovation for €2,2 million, for a total of €3,9 million. Acticor Biotech is strengthening its cash position in the perspective of the preparation of the first clinical phase II for its lead candidate ACT017.
Dr Gilles Avenard, CEO of Acticor Biotech, commented: “We are pleased to welcome Primer Capital as a new international investor and Mr Timur Avdeenko as Observer of the Board. We would like also to thank our historical shareholders including CapDecisif management and Anaxago for their trust and financial support as we are now getting close to the end of our phase I in healthy volunteers and are preparing our first phase II in Acute Ischemic Stroke as add-on to rtPA (Alteplase®). We aim to enroll our first stroke patients treated with ACT017 in June 2018.”
“This drug has a high potential to become an agent of choice and a gold standard, solving unmet demand of the patients with acute phase of ischemic stroke. According to our expert review, market valuation, and significant volume of competitors-free niche, this drug development is very promising for investments,” comments Primer Capital COO Elizaveta Rozhdestvenskaya.
About Primer Capital
Primer Capital is a venture biotech capital fund investing in projects from different areas of pharmaceutical and biotech industry, from oncology, cardiology or rheumatology to surgery.
About Acticor Biotech
Acticor Biotech is a clinical stage biotechnology company, spin-off of Inserm founded in 2013, dedicated to developing an innovative treatment in the therapy of acute thrombotic diseases, including ischemic stroke and pulmonary embolism. Acticor Biotech is built upon the expertise and the results of researches conducted by, the founders: Dr. Martine Jandrot-Perrus at INSERM Paris and Pr. Philippe Billiald at Paris-Sud University. For more information: https://acticor- biotech.com/
About ACT017, the Therapeutic Candidate
Acticor is developing ACT017, a humanized Antibody Fragment (Fab). The therapeutic candidate is directed against a novel target of major interest, platelet glycoprotein VI (GPVI), and inhibits its action. Evidence of antithrombotic efficacy of ACT017 and safety of inhibition of GPVI have been established both ex vivo and in vivo. The target is involved in the growth of the thrombus, but not in physiological haemostasis. This limits the bleeding risk associated with its inhibition.
Chief Executive Officer
Media – NewCap:
+33(0) 1 44 71 00 12 / +33(0) 6 88 20 35 59
Read next in 'Press Releases'
- ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS
- Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer
- Acticor Biotech first-in-human clinical trial in healthy volunteers
- Acticor reached the milestones triggering the second payment in the Research Agreement with its pharma partner Mediolanum
- Acticor Biotech has selected its Contract Research Organisation to manage Clinical Study Phase I